BrainStorm Cell Strengthens Intellectual Property Position - Granted Patent For Company's NurOwn Technology Platform
Published: Oct 16, 2015
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Oct. 16, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Company has been granted a patent by the Israeli Patent Office for BrainStorm's application, titled "Isolated Population of Cells, Methods of Generating Same, and Uses Thereof in the Treatment of CNS Diseases". This patent is held jointly with Ramot, Tel Aviv University's technology transfer company.
The granted claims include neurotrophic factor-secreting cells derived from mesenchymal stem cells, methods for producing those cells and methods of using those cells for the treatment of neurologic diseases. This patent strengthens BrainStorm's NurOwn®-related intellectual property portfolio, particularly in Israel, where the Company has already completed two clinical trials in ALS patients.
"This patent granted in Israel further extends the geographic reach of our intellectual property, with similar claims previously granted in the U.S. Given the origin of this technology at the Tel Aviv University, and our strong commitment to our Israeli operations, we are pleased that Israel's Patent Office has now also acknowledged the innovation of our NurOwn® platform technology," stated Chaim Lebovits, BrainStorm's Chief Executive Officer.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 60 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. These forward-looking statements are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
Chief Operating Officer
LifeSci Advisors, LLC
BrainStorm Cell Therapeutics Inc.
US Office: 201-488-0460
Israeli Office: +972-3-9236384
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-strengthens-intellectual-property-position---granted-patent-for-companys-nurown-technology-platform-300161127.html
SOURCE BrainStorm Cell Therapeutics Inc.